• Je něco špatně v tomto záznamu ?

Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study

P. Pozo-Rosich, HC. Detke, S. Wang, D. Doležil, LQ. Li, SK. Aurora, U. Reuter

. 2022 ; 38 (5) : 731-742. [pub] 20220415

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018536

BACKGROUND: Galcanezumab, a monoclonal antibody to calcitonin gene-related peptide, was found to be safe and efficacious for the preventive treatment of chronic migraine based on the randomized, placebo-controlled double-blind period of the REGAIN study. Long-term safety and efficacy were assessed in an open-label extension. METHODS: Patients 18-65 years old with chronic migraine completing the 3-month double-blind period of REGAIN could enter a 9-month open-label extension (OLE; months 4-12). Upon entering the OLE, patients received a 240-mg galcanezumab loading dose, then 120 mg at the next month, with flexible dosing thereafter (120 or 240 mg/month). The primary efficacy measure was the mean change in the number of monthly migraine headache days from double-blind baseline to month 12. Other endpoints included response rates (based on percent reduction in monthly migraine headache days from double-blind baseline to month 12), safety and tolerability. RESULTS: Of patients who completed double-blind treatment, 1022 (99%) entered the OLE, with 81% completing month 12. From a baseline of 19.4 monthly migraine headache days at the beginning of the double-blind period, patients at month 12 in the previous placebo, 120-mg, and 240-mg galcanezumab groups had a mean change of -8.5, -9.0, and -8.0, respectively (SE = 0.43 to 0.55, within-group p's < .001). At month 12, the percentage of patients with ≥50% response was 57%, 57%, and 53%, respectively. Percentage with ≥75% response was 32%, 31%, and 30%, respectively. Percentage with 100% response was 8%, 6%, and 6%, respectively. There were no significant new safety findings during the open-label period. The incidence of discontinuation from the OLE due to adverse events was 5%. CONCLUSION: Galcanezumab was effective, safe, and well-tolerated, with high adherence, for up to 12 months of treatment in patients with chronic migraine. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT02614261; www.clinicaltrials.gov/ct2/show/NCT02614261.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018536
003      
CZ-PrNML
005      
20220804134837.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/03007995.2022.2059975 $2 doi
035    __
$a (PubMed)35392739
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Pozo-Rosich, Patricia $u Headache Unit, Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain $u Headache and Neurological Pain Research Group, Vall d'Hebron Institute of Research (VHIR), Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain
245    10
$a Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study / $c P. Pozo-Rosich, HC. Detke, S. Wang, D. Doležil, LQ. Li, SK. Aurora, U. Reuter
520    9_
$a BACKGROUND: Galcanezumab, a monoclonal antibody to calcitonin gene-related peptide, was found to be safe and efficacious for the preventive treatment of chronic migraine based on the randomized, placebo-controlled double-blind period of the REGAIN study. Long-term safety and efficacy were assessed in an open-label extension. METHODS: Patients 18-65 years old with chronic migraine completing the 3-month double-blind period of REGAIN could enter a 9-month open-label extension (OLE; months 4-12). Upon entering the OLE, patients received a 240-mg galcanezumab loading dose, then 120 mg at the next month, with flexible dosing thereafter (120 or 240 mg/month). The primary efficacy measure was the mean change in the number of monthly migraine headache days from double-blind baseline to month 12. Other endpoints included response rates (based on percent reduction in monthly migraine headache days from double-blind baseline to month 12), safety and tolerability. RESULTS: Of patients who completed double-blind treatment, 1022 (99%) entered the OLE, with 81% completing month 12. From a baseline of 19.4 monthly migraine headache days at the beginning of the double-blind period, patients at month 12 in the previous placebo, 120-mg, and 240-mg galcanezumab groups had a mean change of -8.5, -9.0, and -8.0, respectively (SE = 0.43 to 0.55, within-group p's < .001). At month 12, the percentage of patients with ≥50% response was 57%, 57%, and 53%, respectively. Percentage with ≥75% response was 32%, 31%, and 30%, respectively. Percentage with 100% response was 8%, 6%, and 6%, respectively. There were no significant new safety findings during the open-label period. The incidence of discontinuation from the OLE due to adverse events was 5%. CONCLUSION: Galcanezumab was effective, safe, and well-tolerated, with high adherence, for up to 12 months of treatment in patients with chronic migraine. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT02614261; www.clinicaltrials.gov/ct2/show/NCT02614261.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a monoklonální protilátky $x terapeutické užití $7 D000911
650    _2
$a humanizované monoklonální protilátky $x škodlivé účinky $7 D061067
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    12
$a migréna $x farmakoterapie $x prevence a kontrola $7 D008881
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Detke, Holland C $u Eli Lilly and Company, Indianapolis, IN, USA $1 https://orcid.org/0000000213166064
700    1_
$a Wang, Shufang $u Eli Lilly and Company, Indianapolis, IN, USA $u Now at Sarepta Therapeutics, Cambridge, MA, USA
700    1_
$a Doležil, David $u Prague Headache Center, DADO MEDICAL s.r.o, Prague, Czech Republic
700    1_
$a Li, Lily Q $u Eli Lilly and Company, Indianapolis, IN, USA
700    1_
$a Aurora, Sheena K $u Eli Lilly and Company, Indianapolis, IN, USA $u Now at Impel NeuroPharma, Seattle, WA, USA
700    1_
$a Reuter, Uwe $u Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany
773    0_
$w MED00009520 $t Current medical research and opinion $x 1473-4877 $g Roč. 38, č. 5 (2022), s. 731-742
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35392739 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134830 $b ABA008
999    __
$a ok $b bmc $g 1822231 $s 1169779
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 38 $c 5 $d 731-742 $e 20220415 $i 1473-4877 $m Current medical research and opinion $n Curr Med Res Opin $x MED00009520
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...